Looming Concerns With Gabapentin Oversight: Balancing Safety and Access
Pain Practice · 2026-06 · 26 (5)
DOI: 10.1111/papr.70158 ↗Kurz gefasst
Editorial in der Zeitschrift Pain Practice, online erschienen am 30.04.2026. Verfasst von Saba Javed und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Analgesics, gamma-Aminobutyric Acid, Cyclohexanecarboxylic Acids, Amines. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
Gabapentin is one of the most frequently prescribed analgesic medications in the United States, commonly used for treating neuropathic pain conditions. While generally thought to have a favorable adverse effect profile, emerging data have implicated gabapentin in cases of respiratory depression and overdose‐deaths, especially when combined with opioids and other central nervous system depressants. As a result, a growing number of states have reclassified gabapentin as a Schedule‐V controlled substance. However, such regulations may risk varied unintended consequences, such as restricting access to a valuable nonopioid analgesic and potentially facilitating illicit market activity. As such, vulnerable populations, particularly those in rural and low‐income areas, may face increased barriers to care. This commentary evaluates the rationale for regulating gabapentin, examines the potential risks associated with such oversight, and suggests a way forward to reduce misuse while maintaining access to gabapentin for patients who genuinely need it.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Orthopedic Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Saba Javed, Jay Karri
Zitieren
APA
Javed, S., Driver, L. C., & Karri, J. (2026). Looming Concerns With Gabapentin Oversight: Balancing Safety and Access. Pain Practice, 26(5). https://doi.org/10.1111/papr.70158
Vancouver
Javed S, Driver LC, Karri J. Looming Concerns With Gabapentin Oversight: Balancing Safety and Access. Pain Practice. 2026;26(5). doi:10.1111/papr.70158
BibTeX
@article{Javed2026,
author = {Javed, Saba and Driver, Larry C and Karri, Jay},
title = {Looming Concerns With Gabapentin Oversight: Balancing Safety and Access},
journal = {Pain Practice},
year = {2026},
volume = {26},
number = {5},
doi = {10.1111/papr.70158}
}
EUVIMED